Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 6/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819183 | 0.88 | AR (0.44) | L3MBTL1SQORCNR1DYRK1ADYRK2 | |
| SCHEMBL25482306 | 0.82 | DYRK1A (0.44) | L3MBTL1SQORDYRK1ADYRK2DYRK1B | |
| SCHEMBL26044686 | 0.82 | MEN1 (0.48) | L3MBTL1SQORCNR1MEN1KMT2A | |
| SCHEMBL25819197 | 0.81 | L3MBTL1 (0.44) | L3MBTL1SQORCNR1MEN1KMT2A | |
| SCHEMBL25819126 | 0.80 | L3MBTL1 (0.47) | L3MBTL1SQORCNR1TSHR | |
| SCHEMBL25819100 | 0.80 | L3MBTL1 (0.43) | L3MBTL1SQORCNR1TSHR | |
| SCHEMBL26043794 | 0.79 | L3MBTL1 (0.46) | L3MBTL1SQORCNR1TSHR | |
| SCHEMBL26043793 | 0.79 | MAPT (0.47) | L3MBTL1SQORCNR1DYRK1ADYRK2 | |
| SCHEMBL25935014 | 0.79 | GABRG2 (0.49) | L3MBTL1SQORCNR1MEN1KMT2A | |
| SCHEMBL27301730 | 0.78 | L3MBTL1 (0.56) | L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | L3MBTL1 964/4885MRGPRX4 4263/4885FFAR1 4554/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | L3MBTL1 2040/4885MRGPRX4 3828/4885FFAR1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.